Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors


04 Oct 2023


Cocktail & Poster Display session


Alexandra Lebedeva


Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646


A. Lebedeva1, O.A. Kuznetsova2, M. Fedyanin3, M.V. Ivanov4, A. Tryakin5

Author affiliations

  • 1 Biology Department, Lomonosov Moscow State University, 119991 - Moscow/RU
  • 2 General Medicine Department, Saint-Petersburg State Pediatric Medical University, 194100 - Saint-Petersburg/RU
  • 3 Clinicla Pharmacology And Chemotherapy Dept, National Medical Research Center of Oncology named after N.N. Blokhin, 115478 - Moscow/RU
  • 4 Molecular And Biological Physics, Moscow Institute of Physics and Technology, 141700 - Dolgoprudny/RU
  • 5 Clinical Pharmacology And Chemotherapy Department, National Medical Research Center of Oncology named after N.N. Blokhin, 115478 - Moscow/RU


This content is available to ESMO members and event participants.

Abstract 164P


Molecularly-matched therapy (MMT) is associated with increased response rates and in some cases with improved survival. Next generation sequencing (NGS) - based multigene panels offer a wide range of analyzed markers. There is a need to optimize comprehensive profiling and find the most relevant molecular targets according to tumor type.


Retrospective analysis of NGS reports and clinical data of patients with advanced gastrointestinal tumors was performed. The frequency of detected molecular alterations in each cancer type, the frequency of MMT recommendation were assessed. Efficacy was estimated using progression-free survival (PFS) ratio (PFS2/PFS1).


Between 2019 and 2023, tumor samples from 107 patients with gastrointestinal tumors were analyzed using NGS-based panels (colorectal cancer (CRC) - 64 patients (59%), pancreatic cancer (PCa) - 21 (20%), cholangiocellular cancer (CCC) - 12 (11%), gastric cancer (GC) - 11 (10%). Median age was 58 years, median number of lines before analysis - 2. MMT after NGS was administered to 17 patients (16%). Of these patients 6 samples were assesed as ESCAT I tier (35%), 2 (12%) - ESCAT IIB, 2 (12%) - ESCAT IIIA, 7 (51%) - ESCAT IIIB. PFS2/1 ratio≥1,3 was reached in 10 patients (59%). In the cohort of patients who have not been prescribed MMT, the PFS ratio was available for 42 patients, among whom 11 patients (26%) achieved PFS1/2 ≥1,3 (p=0,005). MMT was the only favorable predictor of PFS2/1 ≥1.3 (HR 0.13; 95% CI 0.03 - 0.50, p=0.003) in univariate analysis. Median overall survival in the MMT and non-MMT groups was 6 and 5 months, respectively (HR=2.07; 95% CI 1.01 - 4.26). Table: 164P

Variables Univariate analysis
HR (95% CI) p value
Age, years ≥60 <60 1,00 0,80 (0,21 -2,91) 0,72
Number of lines before analysis, ≤1 ≥2 1,00 0,67 (0,16 - 2,86) 0,59
Sex, m f 1,60 (0,45 - 5,70) 1,00 0,47
Molecular tumor board Yes No 1,00 0,61 (0,13 - 2,85) 0,53
RAS RASwt RASmut 1,00 (0,28 - 3,61) 1,00 1,00
MMT Yes No 1,00 0,13 (0,03 - 0,50) 0,003


MMT may potentially have advantages over non-MMT in advanced gastrointestinal cancers when standard therapy options are limited. In order to optimize testing in routine practice, it is necessary to create more limited panels for profiling according to each tumor type.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.